Drug intelligence / Profile preview

NLS-10

Development stage: Preclinical
Lead developer: NLS Pharmaceutics
Modality: Small Molecules
Administration: Oral

Overview

NLS-10 is a preclinical-stage small molecule drug candidate being developed by NLS Pharmaceutics. It is characterized as a long-acting stimulant intended for the treatment of neurodevelopmental disorders. As part of NLS Pharmaceutics' pipeline, which focuses on central nervous system (CNS) therapies for conditions like ADHD and narcolepsy, NLS-10 is designed to address unmet needs in neurodevelopmental health. While the specific molecular targets (such as specific neurotransmitter transporters or receptors) have not been publicly disclosed by the developer, the compound is categorized within their stimulant-based portfolio aimed at improving cognitive and behavioral symptoms.

Other names: Long Acting Stimulant

Beyond the preview

Go deeper on NLS-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLS-10.

Explore the full profile